Skip to main
DMAC

DMAC Stock Forecast & Price Target

DMAC Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DiaMedica Therapeutics Inc has reported positive interim Phase 2 results for its DM199 product candidate in the treatment of preeclampsia, highlighting a statistically significant reduction in blood pressure without placental transfer, which enhances the prospects for subsequent cohort enrollment. The company's innovative approach using recombinant KLK1 mechanism positions DM199 favorably for treating acute ischemic stroke patients who may not benefit from traditional thrombolytic therapy, thus broadening its potential market. As a result of these developments, there has been an increase in expectations surrounding the company's stock value, reflecting confidence in its clinical pipeline and therapeutic applications.

Bears say

DiaMedica Therapeutics's financial outlook is negatively impacted by several key factors, including the historical underperformance of its developmental candidates in extending gestation in preeclampsia and the associated risks tied to ineffective commercial revenue generation. Additionally, the company faces significant challenges related to securing sufficient capital to sustain its operations and ongoing clinical programs, which may hinder future development and commercialization efforts. Compounding these issues, there are critical safety concerns related to its products, particularly the potential adverse effects associated with DM199 and the unclear mechanisms for some of its risks, which may adversely affect patient health and limit market acceptance.

DMAC has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DiaMedica Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DiaMedica Therapeutics Inc (DMAC) Forecast

Analysts have given DMAC a Strong Buy based on their latest research and market trends.

According to 4 analysts, DMAC has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DiaMedica Therapeutics Inc (DMAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.